Ventripoint Diagnostics Appoints Thomas Brown as Director of Congenital Heart Defect Program

Core Insights - Ventripoint Diagnostics Ltd. has appointed Thomas Brown as Director of the Congenital Heart Defect (CHD) Program to enhance its market leadership in pediatric cardiology [1][3] - Mr. Brown has over 20 years of experience in medical imaging sales and market expansion, previously serving as Vice President of North American Sales at Intelligent Ultrasound [2][5] - The appointment aims to accelerate the adoption of Ventripoint's VMS+™ technology in the CHD segment and related markets such as cardio-oncology and heart failure [3][4] Company Strategy - The appointment of Mr. Brown is part of Ventripoint's multi-segment growth strategy, focusing on innovative imaging solutions [4] - Ventripoint's VMS+™ technology offers MRI-comparable cardiac volumetric analysis using standard 2D ultrasound, which reduces costs and wait times for clinicians and patients [4][7] - The company aims to expand its product applications across various ultrasound systems, supported by regulatory approvals in the U.S., Europe, and Canada [7]